ABBV vs HSIC
By Alex · Tickerpine
AbbVie Inc. vs Henry Schein, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | HSIC |
|---|---|---|
| Price | $285.64 | $84.96 |
| Market cap | $504.76B | $9.47B |
| P/E ratio | 80.5 | 24.8 |
| ROE | — | 8.85% |
| Profit margin | 9.80% | 2.96% |
| Revenue growth | 10.20% | 6.70% |
| Dividend yield | 2.42% | 0.00% |
| Beta | 0.23 | 0.84 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs HSIC in plain English
- ABBV is the bigger company — about 53.3× the market cap of HSIC.
- HSIC is cheaper on earnings (P/E 24.8 vs 80.5).
- ABBV is growing revenue faster (10% vs 7%).
- ABBV pays a dividend (2.42%) while the other effectively doesn't.
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
HSIC return calculator
See what $1,000 in Henry Schein, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.